Kelmendi B

Mystical but not challenging experiences predict symptom improvement after psilocybin for treatment-resistant OCD.

Shnayder S, Agin-Liebes G, Hubert TJ +5

Surrender, disidentification, and reappraisal: a qualitative comparison of psilocybin responders and non-responders in treatment-resistant OCD.

Agin-Liebes G, Shnayder S, Fram G +6

α<sub>2</sub>-Adrenergic receptor modulates 5-HT<sub>2A</sub>-mediated behavioral effects of MDMA and psilocybin in mice.

Rosado AF, Yu AL, Yang JH +13

Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD

Shnayder S, Agin-Liebes G, Hubert T +5

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial

Kelmendi B, Adams T, Ching THW +16

Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.

Ching THW, Stahnke B, Shnayder S +22

Europe PMC2025

A Field-Wide Review and Analysis of Study Materials Used in Psilocybin Trials: Assessment of Two Decades of Research.

Yaden DB, Graziosi M, Owen AM +39

Europe PMC2025

Psilocybin Therapy for Clinicians With Symptoms of Depression From Frontline Care During the COVID-19 Pandemic: A Randomized Clinical Trial.

Back AL, Freeman-Young TK, Morgan L +12

Novel Pharmacologic and Other Somatic Treatment Approaches for Posttraumatic Stress Disorder in Adults: State of the Evidence.

Sippel LM, Hamblen JL, Kelmendi B +10

Mechanisms of therapeutic change after psychedelic treatment in OCD.

Maloney G, Ching T, Kichuk SA +2

Corrigendum: Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +16

Methylone is a rapid-acting neuroplastogen with less off-target activity than MDMA.

Warner-Schmidt J, Stogniew M, Mandell B +3

Safety, feasibility, tolerability, and clinical effects of repeated psilocybin dosing combined with non-directive support in the treatment of obsessive-compulsive disorder: protocol for a randomized, waitlist-controlled trial with blinded ratings.

Ching THW, Amoroso L, Bohner C +15

Misinterpretations and Omissions: A Critical Response to Goodwin and Colleagues' Commentary on Psilocybin-Assisted Therapy.

O'Donnell KC, Anderson BT, Barrett FS +9

ArticlePsychedelics

What Is in a Name? The Many Meanings of "Psychedelic".

O'Donnell KC, Roberts DE, Ching THW +8

Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.

Raison CL, Sanacora G, Woolley J +31

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive-compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial.

Ching THW, Grazioplene R, Bohner C +14

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin Combined with Non-Directive Support in the Treatment of OCD

Ching THW, Grazioplene R, Pittenger C +1

Pharmacological effects of methylone and MDMA in humans.

Poyatos L, Pérez-Mañá C, Hladun O +13

Methylone, a rapid acting entactogen with robust anxiolytic and antidepressant-like activity.

Warner-Schmidt J, Pittenger C, Stogniew M +3

Single-dose psilocybin for treatment-resistant obsessive-compulsive disorder: A case report.

Kelmendi B, Kichuk SA, DePalmer G +4

Yale Program for Psychedelic Science (YPPS) Manual for Psilocybin-OCD Session Monitors for Protocol HIC: 2000020355

Ching THW, Kichuk S, DePalmer G +2

ArticlePsychedelics

Psychedelics.

Kelmendi B, Kaye AP, Pittenger C +1

Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies.

Niles H, Fogg C, Kelmendi B +1

Europe PMC2021